Cagrilintide + Semaglutide calculator
The investigational fixed combination of the amylin analog cagrilintide with the GLP-1 agonist semaglutide, developed for greater weight loss.
Also known as: CagriSema, Amylin + GLP-1 combination
FDA status — not an approved drug Not FDA-approved. CagriSema (cagrilintide with semaglutide) is an investigational combination in clinical development and has not been approved.
Schedule Cagrilintide + Semaglutide → Set your dosing schedule and get a phone notification when each dose is due. Free.
What Cagrilintide + Semaglutide is
CagriSema is an investigational once-weekly injection combining two appetite-regulating hormones: cagrilintide, an amylin analog, and semaglutide, a GLP-1 receptor agonist. It was developed to exceed the weight loss of either component alone, and phase 3 results reported large average reductions.
Research depth: 4/5 Completed phase 3 human trials of the combination; not yet approved. Human trials: Phase 3 complete. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How Cagrilintide + Semaglutide works
The two components act on separate gut-hormone receptors. Semaglutide activates GLP-1 receptors; cagrilintide activates amylin receptors. Engaging both pathways simultaneously is intended to additively reduce appetite and food intake, which is the basis for combining them.
Cagrilintide + Semaglutide side effects
Commonly reported
- Nausea, vomiting, and other gastrointestinal effects
- Decreased appetite
- Constipation
Serious — seek medical care
- Gastrointestinal effects consistent with both component classes
- Pancreatitis and gallbladder risk under study
- Long-term combination safety not yet established
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL. A 2400 mcg dose is then 0.48 mL — about 48 units on a 100-unit insulin syringe, giving roughly 4 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable Cagrilintide + Semaglutide dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for Cagrilintide + Semaglutide run from 2400 mcg to 2400 mcg. The combination is dosed once weekly after titration, with each component at a fixed amount. Figures reflect published phase 3 dosing. This is investigational data, not a prescribing guide.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use Cagrilintide + Semaglutide at all are decisions for a licensed clinician who knows your history.
Common questions
What is CagriSema?
CagriSema is the development name for a fixed combination of cagrilintide (an amylin analog) and semaglutide (a GLP-1 agonist) in a single once-weekly injection, designed to produce more weight loss than either alone.
Is CagriSema approved?
No. It is an investigational combination that has completed phase 3 studies but has not been approved.